Pictured: Business partners discussing the terms of a contrac/iStock, AmnajKhetsamtip

图为：商业伙伴讨论合同条款

Daiichi Sankyo announced on Friday that it has won its patent arbitration dispute with Seagen, which will pay the Japanese multinational $47 million in attorneys’ fees and costs, plus interest.

周五，第一三共宣布，它已赢得与Seagen的专利仲裁纠纷，Seagen将向这家日本跨国公司支付4700万美元的律师费和费用以及利息。

Seagen and Daiichi Sankyo have for years been locked in a patent battle over technologies used in the Japanese pharma’s AstraZeneca-partnered antibody-drug conjugate (ADC) Enhertu (fam-trastuzumab deruxtecan-nxki). In August 2022, an arbitrator ruled in favor of Daiichi Sankyo finding that Seagen’s claims were invalid..

多年来，Seagen和Daiichi Sankyo一直在就日本制药公司阿斯利康合作的抗体药物偶联物（ADC）Enhertu（fam曲妥珠单抗deruxtecan nxki）中使用的技术进行专利争夺。2022年8月，一名仲裁员做出了有利于第一三共的裁决，裁定希根的索赔无效。。

According to Daiichi Sankyo, the arbitrator awarded the company around $45.5 million in attorneys’ fees and costs, which Seagen challenged and sought to have vacated. However, a federal court denied the appeal on April 2024 and tacked on interest to Daiichi Sankyo’s award for a total of $47 million..

据第一三共（Daiichi Sankyo）称，仲裁员裁定该公司支付约4550万美元的律师费和费用，希根（Seagen）对此提出质疑，并试图将其撤走。然而，联邦法院于2024年4月驳回了上诉，并对第一三共的裁决增加了4700万美元的利息。。

Pfizer, which acquired Seagen for $43 billion in March 2023, failed to appeal the ruling before a set deadline, officially handing Daiichi Sankyo the victory.

辉瑞于2023年3月以430亿美元收购了希根，但未能在规定的截止日期前对裁决提出上诉，正式将胜利交给了第一三共。

Despite Friday’s win, the larger patent battle between Pfizer and Daiicihi Sankyo may not yet be over. In January 2024, the U.S. Patent and Trademark Office ruled that Seagen’s contentious patent 10,808,039—which protects the use of auristatin peptides in ADCs via a specific linker technology—is invalid..

尽管周五取得了胜利，但辉瑞与Daicihi Sankyo之间规模更大的专利大战可能尚未结束。2024年1月，美国专利和商标局裁定，Seagen的有争议的专利10808039通过特定的接头技术保护在ADC中使用auristatin肽是无效的。。

Seagen has also racked up legal victories in recent years. A civil action suit it filed in 2020—over the same patent infringement issue—ended in a jury victory in April 2022, awarding the company $41.82 million in damages. The District Court for the Eastern District of Texas also ruled in favor of Seagen in October 2023 with Daiichi Sankyo having to pay 8% royalty on all Enhertu sales from April 1, 2022 through November 4, 2024..

近年来，希根也取得了法律上的胜利。。德克萨斯州东区地方法院也于2023年10月裁定Seagen胜诉，第一三共必须支付2022年4月1日至2024年11月4日期间所有Enhertu销售额的8%版税。。

The patent dispute between Seagen and Daiichi Sankyo stretches back to 2008, when they signed a partnership that used Seagen’s ADC technology to develop therapies against solid tumors, according to Genetic Engineering & Biotechnology News. The collaboration ended in 2015.

据《基因工程与生物技术新闻》（Genetic Engineering&Biotechnology News）报道，Seagen和Daiichi Sankyo之间的专利纠纷可以追溯到2008年，当时他们签署了一项合作协议，利用Seagen的ADC技术开发针对实体瘤的疗法。合作于2015年结束。

In 2019, Seagen claimed that Daiichi Sankyo owed it a portion of the Japanese pharma’s $6.9 billion contract with AstraZeneca. Enhertu, which at the time was still under development and was the centerpiece of the AstraZeneca deal, used underlying technology that was formed between 2008 and 2015 when the companies were still partners, Seagen alleged..

2019年，希根（Seagen）声称，第一三共（Daiichi Sankyo）欠它这家日本制药公司与阿斯利康（AstraZeneca）69亿美元合同的一部分。希根声称，Enhertu当时仍在开发中，是阿斯利康交易的核心，它使用了2008年至2015年间形成的基础技术，当时两家公司仍然是合作伙伴。。

In response, Daiichi Sankyo filed a Declaratory Judgement in November 2019 maintaining that Seagen’s claims were without merit.

作为回应，Daiichi Sankyo于2019年11月提交了一项宣告性判决，坚称Seagen的索赔没有依据。

Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

特里斯坦·马纳拉克（TristanManalac）是一位独立的科学作家，总部位于菲律宾大马尼拉。在LinkedIn上联系他，或发电子邮件给他tristan@tristanmanalac.com或tristan.manalac@biospace.com.